These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1873770)

  • 1. Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
    Arlin ZA; Feldman EJ; Mittelman A; Ahmed T; Puccio C; Chun HG; Cook P; Baskind P; Marboe C; Mehta R
    Cancer; 1991 Sep; 68(6):1198-200. PubMed ID: 1873770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone and amsacrine: two important agents for the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL).
    Arlin ZA
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():57-9. PubMed ID: 2653519
    [No Abstract]   [Full Text] [Related]  

  • 3. Amsacrine: a review.
    Cassileth PA; Gale RP
    Leuk Res; 1986; 10(11):1257-65. PubMed ID: 3540460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amsacrine is safe in patients with ventricular ectopy.
    Puccio CA; Feldman EJ; Arlin ZA
    Am J Hematol; 1988 Jul; 28(3):197-8. PubMed ID: 2457309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
    Arlin ZA; Ahmed T; Mittelman A; Feldman E; Mehta R; Weinstein P; Rieber E; Sullivan P; Baskind P
    J Clin Oncol; 1987 Mar; 5(3):371-5. PubMed ID: 3546613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
    Krejci M; Doubek M; Dusek J; Brychtova Y; Racil Z; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
    Ann Hematol; 2013 Oct; 92(10):1397-403. PubMed ID: 23728608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
    Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
    J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia.
    Reman O; Buzyn A; Lhéritier V; Huguet F; Kuentz M; Stamatoullas A; Delannoy A; Fegueux N; Micléa JM; Boiron JM; Vernant JP; Gardin C; Hacini M; Georges M; Fière D; Thomas X;
    Hematol J; 2004; 5(2):123-9. PubMed ID: 15048062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
    Fong CY; Grigoriadis G; Hocking J; Coutsouvelis J; Muirhead J; Campbell P; Paul E; Walker P; Avery S; Patil S; Spencer A; Schwarer A; Wei A
    Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment.
    Maschmeyer G; Willborn K; Heit W
    Leuk Lymphoma; 1992 Nov; 8(4-5):365-9. PubMed ID: 1290961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
    Willemze R; Suciu S; Archimbaud E; Muus P; Stryckmans P; Louwagie EA; Berneman Z; Tjean M; Wijermans P; Dohner H; Jehn U; Labar B; Jaksic B; Dardenne M; Zittoun R
    Leukemia; 1997 Mar; 11 Suppl 1():S24-7. PubMed ID: 9130688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
    Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
    N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group.
    Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA
    Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine.
    Carter C; Winfield DA
    Clin Lab Haematol; 1988; 10(2):225-8. PubMed ID: 3166416
    [No Abstract]   [Full Text] [Related]  

  • 20. A special role for amsacrine in the treatment of acute leukemia.
    Arlin ZA
    Cancer Invest; 1989; 7(6):607-9. PubMed ID: 2630010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.